(MedPage Today) — ORLANDO — Among children taking the monoclonal antibody dupilumab (Dupixent) for atopic dermatitis, more than a quarter of ocular complications developed after a year, according to a retrospective cohort study.
Of the children…
Source link : https://www.medpagetoday.com/meetingcoverage/aao/118085
Author :
Publish date : 2025-10-22 18:18:00
Copyright for syndicated content belongs to the linked Source.
